5-MAPBT

5-MAPBT, also known as 5-(2-(methylamino)propyl)-1-benzothiophene, is a possible entactogen of the phenethylamine, amphetamine, and benzothiophene families.^{[2][3] [4]} It is closely related to 5-MAPB, but with the oxygen atom replaced by sulfur, changing the core ring structure to benzothiophene rather than benzofuran.^[4]

Other names5-(2-(Methylamino)propyl)-1-benzothiophene; MY400; MY-400^[1]

Drug classMonoamine releasing agent; Serotonin 5-HT_1B receptor agonist; Entactogen

ATC code

• None

CAS Number

• 2613382-32-2 ^Y

Quick facts Clinical data, Other names ...

5-MAPBT

Clinical data
Other names	5-(2-(Methylamino)propyl)-1-benzothiophene; MY400; MY-400[1]
Drug class	Monoamine releasing agent; Serotonin 5-HT1B receptor agonist; Entactogen
ATC code	None
Identifiers
IUPAC name 1-(1-benzothiophen-5-yl)-N-methylpropan-2-amine
CAS Number	2613382-32-2 Y
PubChem CID	165889699
ChemSpider	103843875
Chemical and physical data
Formula	C12H15NS
Molar mass	205.32 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(CC1=CC2=C(C=C1)SC=C2)NC
InChI InChI=1S/C12H15NS/c1-9(13-2)7-10-3-4-12-11(8-10)5-6-14-12/h3-6,8-9,13H,7H2,1-2H3 Key:SKSFWFUEBKJIAJ-UHFFFAOYSA-N

Close

The drug acts as a potent monoamine releasing agent, including of serotonin and dopamine, and as a potent serotonin 5-HT_1B receptor agonist and serotonin 5-HT_2B receptor antagonist.^[4] It is also a monoamine oxidase A (MAO-A) inhibitor, with an IC₅₀Tooltip half-maximal inhibitory concentration of 765 nM.^[4]

It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents.^[4] However, benzothiophenes like 5-MAPBT, despite their induction of dopamine release, are said to lack hyperlocomotion or stimulant-like effects in rodents.^[3][5]

5-MAPBT has been studied and patented by Matthew J. Baggott at Tactogen.^[4] The drug has also been patented by Mydecine and given the developmental code name MY400.^[6]